Hubert BirnerManaging Partner at TVM CapitalSpeaker
Dr. Hubert Birner a Managing Partner of TVM Capital and responsible for the company’s worldwide venture capital strategy for life sciences. He has been with TVM since October 2000. Hubert has had one of the longest active careers in European Venture Capital and has successfully managed/overseen more than 50 investments for TVM. In total, he is overseeing all portfolio investments from 4 TVM funds currently.
He currently serves as Chairman of the Board of AL-S Pharma AG (Zurich, Switzerland), leon-nanodrugs (Munich, Germany) and Spepharm Holdings BV (Amsterdam, the Netherlands), he is also a Supervisory Board Member of Centogene AG (NASDAQ).
For many years, he has been the Chairman/Vice Chairman of the Board of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany, XETRA) which were both acquired by Bayer HealthCare AG and Shire Ltd. as the largest acquisitions in the history of Germany biotechnology. It is also noteworthy that his investments in Horizon Therapeutics and Evotec triggered their transformation into multi-billion-dollar public companies today.
Hubert has also successfully designed and implemented a new “asset centric” project financing investment model for biotechnology/early pharmaceutical companies in close cooperation with Eli Lilly & Company.
Prior to his tenure at TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany for Zeneca Agrochemicals, headquartered in London, UK. In this context, Hubert did manage his first biotechnology investments. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development.
Hubert also holds an MBA from Harvard Business School.